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Abstract
Background: Macrophages (MΦs) utilize macropinocytosis to integrate immune and metabolic
signals in order to initiate an effective immune response. Diabetes is characterized by metabolic
abnormalities and altered immune function. Here we examine the influence of diabetes on
macropinocytosis in primary mouse macrophages and in an in vitro diabetes model.
Results: The data demonstrate that peritoneal MΦs from diabetic (db/db) mice had reduced
macropinocytosis when compared to MΦs from non-diabetic (db/+) mice. Additionally, MΦs
cultured in hyperglycemic conditions were less adept at macropinocytosis than those cultured in
low glucose. Notably, AMP-activated protein kinase (AMPK) activity was decreased in MΦs
cultured in hyperglycemic conditions. Activation of AMPK with leptin or 5-aminoimidazole-4-
carboxamide-1-β-riboside (AICAR) increased macropinocytosis and inhibition of AMPK with
compound C decreased macropinocytosis.
Conclusion: Taken together, these findings indicate that MΦs from diabetic mice have decreased
macropinocytosis. This decrease appears dependent on reduced AMPK activity. These results
demonstrate a previously unrealized role for AMPK in MΦs and suggest that increasing AMPK
activity in diabetic MΦs could improve innate immunity and decrease susceptibility to infection.
Background
MΦs are critical mediators of various immune functions.
One of the most important actions the MΦ plays is coor-
dinating innate and adaptive immunity. To do this, MΦs
must integrate signals from the local microenvironment
with signals from the entire organism to assume an appro-
priate phenotype [1]. One of the ways MΦs do this is
through macropinocytosis or 'drinking' large amounts of
extracellular fluid. Macropinocytosis is characterized by
the uptake of fluid through relatively large vacuoles (up to
5 microns) [2,3]. This process is similar to phagocytosis in
a number of ways including the formation of an actin-rich
ruffle with a structure similar to a pseudopodia and PI3-
kinase dependent rearrangement of the plasma mem-
brane [2,3]. However, these processes differ in some ways
[2,3]. One of these differences is that phagocytosis utilizes
ligand specific receptors while macropinocytosis is rela-
tively non-specific allowing for a rapid unsaturable sam-
pling of the heterogenous surrounding fluid including
nutrients and pathogens. This fluid is concentrated and
acidified in lysosomes, which usually destroy any patho-
gens contained within. The peptides are then processed
and, in the case of professional antigen presenting cells,
these peptides are shuttled back to the cell membrane in
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the context of MHC-II and can participate in the activation
of T-cells [4]. Thus, macropinocytosis acts as a bridge
between innate and adaptive immunity.
In the last decade, our understanding of how metabolism
and immunity interact has grown a great deal. These com-
plex systems share numerous components that are critical
to ensure the fitness of an organism. One of the best
examples of this interdependence is seen in diabetes. Dia-
betes is characterized by an inability to efficiently utilize
glucose. As a result, those with diabetes are plagued by
pathological complications including chronic inflamma-
tion [5-7] and a susceptibility to infectious pathogens
including  Staphylococcus aureus,  Streptococcus pneumonia
and  Mycobacterium tuberculosis [8]. Another important
modulator that is altered in diabetes is leptin. Leptin is a
16 kDa protein that is primarily secreted by adipose tissue
and is structurally similar to the long-chain helical
cytokine family including IL-6 [9]. It is recognized as an
indicator of whole body energy levels and acts as a regula-
tor of satiety in the hypothalamus [10]. However, studies
with mice lacking a functional leptin system display a
wide range of defects including impaired wound healing
[11,12], increased uptake of modified LDL [13] and
decreased phagocytosis of Klebsiella pneumoniae [14] indi-
cating that leptin plays a significant function in immunity.
Notably, several studies have shown that leptin activates
AMPK in a number of cell types outside the central nerv-
ous system [15,16]. AMPK is well known as a master reg-
ulator of intracellular energy status, but recent work has
also alluded to a roll as a key regulator of immune cell
function including cytokine secretion [17,18] and chemo-
taxis [19]. In addition, activation of AMPK has been
shown to improve some of the symptoms of diabetes
[20]. Given the alterations to the immune system found in
diabetes, we wanted to see if MΦs from diabetic mice had
decreased macropinocytosis and, if so, determine which
factors contributed to this alteration. Importantly, we
found that macropinocytosis was decreased in MΦs cul-
tured in hyperglycemic conditions and indicate that this
decrease was caused by decreased AMPK activation.
Results and discussion
Peritoneal MΦs from diabetic (db/db) mice and MΦs 
cultured in diabetic conditions have decreased 
macropinocytosis
To determine if MΦ macropinocytosis was affected by dia-
betes, peritoneal MΦs were isolated from diabetic db/db
mice and from non-diabetic db/+ mice and macropinocy-
tosis was tested. Figure 1A demonstrates that peritoneal
MΦs from db/db mice displayed diminished macropinoc-
ytosis when compared to MΦs from db/+ controls (p <
0.001). To determine which components of the diabetic
milieu decreased macropinocytosis, the mouse MΦ cell
line, RAW 264.7, was cultured for 24 h and 48 h in low
glucose (1 g/L) and high glucose (4.5 g/L)/high insulin (1
nM) conditions observed in db/db mice [13]. MΦs cul-
tured for 24 h in low glucose conditions had a 15%
increase in the uptake of FITC-albumin when compared
to cells cultured in high glucose/high insulin conditions
(p = 0.02) (Figure 1B). When the duration of the culture
was extended to 48 h, the difference increased to 51% (p
< 0.001) (Figure 1B). This difference is further highlighted
in Figure 1C by fluorescent microscopy. Taken together,
these findings indicate that endocytosis of FITC-albumin
by MΦs is decreased in two models of type 2 diabetes.
Peritoneal MΦs from db/db mice and MΦs cultured in dia- betic conditions have decreased macropinocytosis Figure 1
Peritoneal MΦs from db/db mice and MΦs cultured in 
diabetic conditions have decreased macropinocyto-
sis. A, peritoneal MΦs were isolated from non-diabetic (db/+) 
and diabetic (db/db) and FITC-albumin uptake was measured 
by flow cytometry.B, MΦs were cultured in high glucose/high 
insulin conditions for 24 h or 48 h. FITC-albumin uptake was 
measured by flow cytometry. C, MΦs were cultured for 48 h 
in high glucose/high insulin conditions and FITC-albumin 
uptake was visualized by fluorescent microscopy. Results are 
representative of at least three independent experiments ± 
SEM. *: p < 0.05 from low glucose controls.BMC Immunology 2008, 9:42 http://www.biomedcentral.com/1471-2172/9/42
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Macropinocytosis is the fluid-phase endocytic process 
decreased in MΦs cultured in diabetic conditions
MΦs primarily utilize two pathways of fluid-phase endo-
cytosis-macropinocytosis and micropinocytosis. Since
macropinocytosis has been shown to require PI3-kinase
[2], actin polymerization [3] and the PKC pathway [21],
and micropinocytosis does not, we conducted experi-
ments to determine the influence of these elements on the
uptake of FITC-albumin. When cells were treated with the
PI3-kinase inhibitor LY 294002, albumin uptake was
reduced by 84% in cells cultured in low glucose condi-
tions compared to untreated controls (p < 0.001). Simi-
larly, uptake was significantly reduced in cells cultured in
diabetic conditions (p = 0.002) (Figure 2A). In order to
confirm this finding, we cultured cells in both low glucose
and diabetic conditions and treated them with various
concentrations of wortmannin, an alternate PI3-kinase
inhibitor that works through a different mechanism [22].
Figure 2B indicates that treatment with 100 nM wortman-
nin as previously described [23] significantly reduced
uptake in both low glucose (65%; p = 0.001) and diabetic
conditions (89%; p = 0.001). Taken together, these data
indicate that the uptake of FITC-albumin is PI3-kinase
dependent. Next, we wanted to test whether actin polym-
erization regulated the uptake of FITC-albumin. Figure 2C
shows that the uptake of FITC-albumin was inhibited by
cytochalasin D in both low glucose (64%; p = 0.001 at 10
μM) and diabetic conditions (59%; p = 0.003 at 10 μM)
in a dose dependent manner. PKCs have been implicated
as key regulatory elements in macropinocytosis, particu-
larly PKCδ [21]. When cells were treated with a pan-spe-
cific PKC inhibitor, bisindolylmaleimide, FITC-albumin
uptake was reduced by 59% in cells cultured in low glu-
cose conditions (p < 0.001) (Figure 2D). Similarly, uptake
was significantly reduced in cells cultured in diabetic con-
ditions (p = 0.003) (Figure 2E). In order to confirm this
finding and determine which PKC isoform was the domi-
nant regulator, we cultured cells in both low glucose and
diabetic conditions and treated them with various con-
centrations of rottlerin, a specific PKCδ inhibitor [24]. Fig-
ure 2F indicates that treatment with rottlerin significantly
reduced uptake in both low glucose (79%; p < 0.001 at 5
μM) and diabetic conditions (47%; p = 0.006 at 5 μM) in
a dose dependent manner. These data suggest that the
fluid-phase uptake of FITC-albumin is regulated by the
PKC pathway and that PKCδ is the principal isoform. In
summation, these results indicate that macropinocytosis
is the fluid-phase endocytic process that is decreased in
MΦs cultured in diabetic conditions.
MΦs cultured in chronic hyperglycemic conditions have 
decreased macropinocytosis when compared to control 
cells
In order to determine which factors were responsible for
this difference in uptake, we tested whether high glucose,
Uptake of FITC-albumin is dependent on PI3-kinase, actin  polymerization, and PKC-δ Figure 2
Uptake of FITC-albumin is dependent on PI3-kinase, 
actin polymerization, and PKC-δ. A-B, For PI3-kinase 
inhibition studies, MΦs were cultured in diabetic or non-dia-
betic conditions for 48 h and treated with 25 μM LY294002 
or with wortmannin (10 nM or 100 nM) 15 m prior to uptake 
experiments. FITC-albumin uptake was measured by flow 
cytometry. C, MΦs were cultured in diabetic or non-diabetic 
conditions for 48 h and actin polymerization was inhibited by 
the addition of 1–10 μM of cytochalasin D 15 m prior to 
uptake studies. FITC-albumin uptake was measured by flow 
cytometry. D-F, For PKC inhibition studies MΦs were cul-
tured in diabetic or non-diabetic conditions for 48 h and 
treated with 10 μM bisindolylmaleimide or 0.25–5 μM rott-
lerin 15 m prior to uptake experiments. FITC-albumin uptake 
was measured by flow cytometry. Results are representative 
of three independent experiments ± SEM. *: p < 0.05 from 
low glucose controls, *#: p < 0.05 from high glucose 
controls.BMC Immunology 2008, 9:42 http://www.biomedcentral.com/1471-2172/9/42
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osmotic stress, or high insulin altered FITC-albumin
uptake. Cells were cultured at various concentrations of
glucose, mannitol or insulin for 48 h and FITC-albumin
uptake was measured. FITC-albumin uptake decreased as
the concentration of glucose increased. Uptake was
reduced by 55% in cells cultured at 2 g/L glucose (p <
0.001) and 70% at either 3 g/L glucose or 4.5 g/L glucose
(p < 0.001) (Figure 3A). Next, we tested whether this
change was caused by osmotic stress using cells cultured
in 1 g/L glucose with various concentrations of mannitol
added to increase osmolarity to the levels seen in the high
glucose experiments. The addition of mannitol had no
discernible effect on FITC-albumin uptake even at the
highest concentration tested (p = 0.28) (Figure 3B).
Finally, we examined the effect of insulin on FITC-albu-
min uptake by culturing cells at various concentrations of
insulin. Insulin failed to alter FITC-albumin uptake even
at the highest concentration tested (p = 0.27) (Figure 3C).
Taken together these findings indicate that macropinocy-
tosis was decreased by culture in high glucose conditions
and neither insulin nor osmotic stress significantly alter
uptake.
AMP-activated protein kinase activity is decreased in MΦs 
cultured in diabetic conditions and regulates 
macropinocytosis
AMPK is well known as a master regulator of intracellular
energy metabolism [25]. Activation of AMPK has been
found to increase glucose uptake in skeletal muscle [26]
and alleviate some of the complications associated with
diabetes [27-29]. Recently, AMPK has been found to regu-
late primary immune cell functions like chemotaxis [19],
cytokine secretion [17,18] and uptake of Candida albicans
[30]. In order to determine if AMPK played a role in the
decreased macropinocytosis observed in MΦs cultured in
diabetic conditions, we examined the phosphorylation
state of threonine 172 on the α2 subunit of AMPK which
has been shown to be crucial in the activation of AMPK
[31]. AMPK activation was increased by 65% in cells cul-
tured in low glucose conditions when compared to cells
cultured in diabetic conditions (p < 0.001) (Figure 4A–B).
This finding supports previous research indicating that
AMPK is activated by low glucose conditions [32,33] and
decreased in diabetic mice [34]. Next, we examined the
role of AMPK in macropinocytosis by using the AMPK
activator, leptin [15]. MΦs cultured in low glucose condi-
tions demonstrated a dose dependent increase in mac-
ropinocytosis when treated with leptin ranging from 32%
for 6 nM (p < 0.001) to 147% for 620 nM (p < 0.001)
when compared to controls (Figure 4C). MΦs cultured in
diabetic conditions also showed a dose dependent
response to leptin treatment, although it was less pro-
nounced, with uptake being significantly increased at the
highest concentration of leptin tested (38%; p = 0.04)
(Figure 4C). This attenuated response suggests a state of
cytokine resistance. Cytokine resistance is a normal phys-
iological counter-regulatory mechanism that decreases
the potency of cytokines or other growth factors after
repeated stimulation. However, chronic over-stimulation,
as seen in diseases like diabetes, can lead to over-expres-
sion of suppressor-of-cytokine-signaling (SOCS) proteins
which can inhibit off target receptors leading to immune
or metabolic dysfunction [35]. We and others have
reported that SOCS proteins are upregulated in diabetic
MΦs [36] and inhibit leptin mediated activation of AMPK
[37]. In order to further investigate this finding, we uti-
lized a classical activator of AMPK, AICAR, which acts
downstream of SOCS. AICAR is a cell permeable activator
of AMPK that functions as a mimetic of AMP to facilitate
phosphorylation by LKB1 [38] or CaMKK on the α2 sub-
unit of AMPK [39]. MΦs cultured in low glucose exhibited
a 100% increase in macropinocytosis when treated with 1
mM AICAR (p = 0.002). Macrophages cultured in high
Hyperglycemia reduced macropinocytosis while neither  osmotic stress nor high insulin altered uptake Figure 3
Hyperglycemia reduced macropinocytosis while nei-
ther osmotic stress nor high insulin altered uptake. A, 
MΦs were cultured for 48 h at the glucose concentrations 
indicated and FITC-albumin uptake was measured by flow 
cytometry. B, MΦs were cultured for 48 h in low glucose 
with mannitol at the concentrations indicated. FITC-albumin 
uptake was measured by flow cytometry. C, MΦs were cul-
tured for 48 h in low glucose with insulin at the concentra-
tions indicated. FITC-albumin uptake was measured by flow 
cytometry. Results are representative of three independent 
experiments ± SEM. *: p < 0.05 from low glucose controls.BMC Immunology 2008, 9:42 http://www.biomedcentral.com/1471-2172/9/42
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glucose exhibited an increase of 244% when treated with
1 mM AICAR (p < 0.001) compared to untreated high glu-
cose controls (Figure 4D). Interestingly, this finding may
indicate that other types of immunological and metabolic
abnormalities caused by cytokine resistance can be atten-
uated or reversed by activating AMPK by pathways inde-
pendent of receptor mediated activation. Finally, in order
to further test whether AMPK was a critical regulator of
macropinocytosis, we used the AMPK inhibitor, com-
pound C [40,41]. Chronic treatment with compound C
significantly decreased macropinocytosis in MΦs cultured
in either low glucose (28%; p < 0.001) or diabetic condi-
tions (27%; p = 0.017) (Figure 4E). Importantly, FITC-
albumin uptake was not completely abolished by treat-
ment with compound C at the concentration used, indi-
cating that there are other important factors that regulate
macropinocytosis. Taken together, these results indicate
that the decreased macropinocytosis observed in MΦs cul-
tured in diabetic conditions is caused by decreased AMPK
activation.
Conclusion
MΦs must be capable of adapting to diverse immune and
metabolic environments ranging from the hypoxic, nutri-
ent poor surroundings of a necrotic tumor to the well oxy-
genated nutrient rich environment of the lung. In order to
provide the energy necessary to perform their immune
functions, MΦs either utilize glycolysis or oxidative phos-
phorylation. Work by Odegaard et al., shows that this
switch is a critical determinant of macrophage phenotype
and function [42]. Additionally, they showed that disrup-
tion of this phenotypic switch may be an important com-
ponent of insulin resistance and hyperglycemia.
Macropinocytosis is a highly energetic process requiring
extensive restructuring of the plasma membrane and the
coordination several pathways including PI3-kinase and
PKCs. One of the key enzymes regulating the transition
from oxidative phosphorylation to glycolysis is AMPK.
Interestingly, since PI3-kinase and PKCs are involved in
numerous other endocrine and immune roles, AMPK may
be a critical mediator of these other functions. Further-
more, our findings present new evidence that demon-
strate a novel role for AMPK in regulating an important
aspect of innate immunity and indicate a central role for
AMPK in determining macrophage phenotype. In addi-
tion, we also show that diabetic conditions, particularly
hyperglycemia, can impair macropinocytosis through
decreased AMPK activation. Further work needs to be
done to determine the role of AMPK in the regulation of
macrophage phenotype and function in health and dis-
ease and how AMPK interacts with other known regula-
tors of macrophage function (Figure 5).
AMP-activated protein kinase activity is decreased in MΦs  cultured in diabetic conditions and regulates macropinocyto- sis Figure 4
AMP-activated protein kinase activity is decreased in 
MΦs cultured in diabetic conditions and regulates 
macropinocytosis. A-B, MΦs were cultured for 48 h in low 
glucose or high glucose and α2 AMPK activity was measured 
by Western analysis. C, MΦs were cultured in low glucose or 
high glucose conditions with leptin at the concentrations 
indicated. FITC-albumin uptake was measured by flow 
cytometry. D, MΦs were cultured in low glucose or high glu-
cose conditions with AICAR at the concentrations indicated. 
FITC-albumin uptake was measured by flow cytometry. E, 
MΦs were cultured in low glucose or high glucose conditions 
with 1 μM compound C. FITC-albumin uptake was measured 
by flow cytometry. Results are representative of three inde-
pendent experiments ± SEM. *: p < 0.05 from low glucose 
controls, *#: p < 0.05 from high glucose controls.BMC Immunology 2008, 9:42 http://www.biomedcentral.com/1471-2172/9/42
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Materials and methods
Materials
The mouse macrophage like cell line, RAW 264.7, was
purchased from American Type Culture Collection (Rock-
ville, MD). All cell culture reagents and chemicals were
purchased from Sigma (St. Louis, MO) except as noted
below. FBS (0.05 ng/mL, 0.48 EU/mL endotoxin) and
Leptin were purchased from Atlanta Biologicals (Nor-
cross, GA). LY 294002 (Cat# 440202), rottlerin (Cat#
557370), 5-Aminoimidazole-4-carboxamide-1-β-riboside
(AICAR) (Cat# 123040), 6-[4-(2-Piperidin-1-yl-ethoxy)-
phenyl)]-3-pyridin-4-yl-pyrrazolo [1,5-a]-pyrimidine
(compound C) (Cat# 171260) and bisindolylmaleimide
(Cat# 203293) were purchased from Calbiochem (La
Jolla, CA). Propidium iodide was purchased from Molec-
ular Probes (Eugene, OR). Anti-AMPKα 1/2 (Cat# sc-
25792), anti-phoso AMPK (Threonine 172) (Cat# sc-
33524-R) and Culture Micro Slides (sc-24978) were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA).
Fluormount G was purchased from Southern Biotechnol-
ogy.
Animals
All animal care and use was conducted in accordance with
the Guide for the Care and Use of Laboratory Animals
(NRC). 8- to 12-week-old B6.Cg-M+/+Leprdb (db/+) and
B6.Cg-+Leprdb/+Leprdb (db/db) were bred in house from
mice purchased from The Jackson Laboratories (Bar Har-
bor, Maine). Mice were housed in standard shoebox cages
and allowed pelleted food (NIH 5K52; LabDiet, Purina
Mills Inc., Brentwood, MO) and water ad libitum in a tem-
perature (72°C) and humidity (45–55%) controlled envi-
ronment with a 12/12-h dark-light cycle (7:00 a.m. – 7:00
p.m.).
Peritoneal Macrophage Isolation
Mice were sacrificed by CO2 asphyxiation and peritoneal
fluid was collected by lavaging the peritoneum twice with
5 ml ice cold low glucose growth media (glucose-free
RPMI 1640 media supplemented with 10% FBS, 1 g/L glu-
cose, 2 g/L sodium bicarbonate, 110 mg/L sodium pyru-
vate, 62.1 mg/L penicillin and 100 mg/L streptomycin, 10
mM HEPES pH 7.4), followed immediately by analysis or
use in ex vivo experiments. For ex vivo experiments, cells
were plated according to the following procedure. Perito-
neal fluid was centrifuged and the resulting pellet resus-
pended in 5 ml of red blood cell lysis buffer (142 mM
NaCl, 118 mM NaEDTA, 1 mM KHCO3 pH 7.4) at room
temperature for 4 minutes. An equal volume of cold low
glucose growth media was added followed by cell pellet-
ing and resuspension in 37°C low glucose growth media.
Cells were counted with the use of a hemocytometer and
plated in culture dishes at 5 × 105 cells/ml in low glucose
growth media. After 30 min, plates were washed twice to
remove non-adherent cells, resulting in approximately
80% pure macrophages, as previously confirmed by
CD11b staining and morphology [13]. Immediately fol-
lowing plating selection, peritoneal macrophages were
used for uptake experiments.
Cell Culture/Insulin and Glucose Treatment
Raw 264.7 cells were grown in RPMI growth media (2 g/L
glucose) as previously described [24]. For glucose and
mannitol treatments, cells were resuspended at 2.5 × 105
cells/ml in low glucose growth media (1 g/L glucose) or
supplemented with additional glucose or mannitol at the
concentrations indicated and grown for 48 h. For chronic
insulin treatments, cells were treated as above with or
without the addition of 1 nm insulin or at the concentra-
tions indicated for 48 h. Cell viability was at least 80% as
determined by PI staining.
Macropinocytosis
Quantitative analysis of macropinocytosis was performed
as described [13,43,44], with minor modifications. Cells
(2.5 × 105) were incubated with 5 μg/mL FITC-albumin at
37°C for 4 h. Macropinocytosis was stopped by 3 washes
in ice-cold wash buffer. Gates were set to exclude PI posi-
tive cells. For PI3-kinase inhibition experiments, 25 μM
LY294002 or wortmannin (10 nM or 100 nM) was added
15 m prior to uptake experiments. For inhibition of actin
polymerization studies, 1–10 μM of cytochalasin D was
added 15 m prior to uptake studies. For PKC inhibition
studies, 10 μM bisindolylmaleimide or 0.25–5 μM rott-
lerin was added 15 m prior to uptake experiments. For
leptin experiments, 6–620 nM leptin was added 48 h prior
to uptake experiments. For AICAR experiments, 50–1000
Summary schematic of the pathways regulating macropinocy- tosis Figure 5
Summary schematic of the pathways regulating mac-
ropinocytosis. AMPK, AMP-activated protein kinase, ERK, 
extracellular-signal-regulated kinase, PI3K, phosphoinositide 
3-kinase, PKC, protein kinase C, SOCS, suppressor of 
cytokine signaling, IRS-2, insulin receptor substrate 2, Jak, 
janus kinase.BMC Immunology 2008, 9:42 http://www.biomedcentral.com/1471-2172/9/42
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μM AICAR was added 48 h prior to uptake experiments.
For compound C experiments, 1 μM compound C was
added 48 h prior to uptake experiments. For fluorescent
imaging studies cell grown in Culture Micro Slides and
treated as indicated. Cells were fixed with 10% formalin
for 15 m and coverslipped with Fluormount G. Cells were
then visualized using the FITC filter.
Western Analysis
Macrophages were lysed in ice-cold lysis buffer and pro-
teins resolved by SDS-PAGE (25 μg/lane) under reducing
conditions in 4–20% gradient gels. After electrotransfer to
nitrocellulose and resolution of proteins with ECL Plus
Kit (Amersham) [36], bands where quantified by densit-
ometry and analyzed using Image J (NIH), The numerical
data reported in the 'results' section is based on the sum-
mary of all blots followed by statistical analysis.
Statistical Analysis
Data are presented as mean ± SEM. Experimental data
were analyzed either by the Student's t-test for compari-
son of means, or by ANOVA using Excel (Microsoft, Red-
mond WA). Statistical significance was denoted at p <
0.05.
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